US FDA advisory committee recommends approval of tacrolimus ointment.
D000328:Adult; D002648:Child; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009824:Ointments; D016559:Tacrolimus / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D007166:Immunosuppressive Agents; D009824:Ointments; D016559:Tacrolimus